Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.99 USD | +2.48% | -6.91% | +12.00% |
Financials (USD)
Sales 2024 * | 35.58M | Sales 2025 * | 26.71M | Capitalization | 655M |
---|---|---|---|---|---|
Net income 2024 * | -163M | Net income 2025 * | -202M | EV / Sales 2024 * | 9.89 x |
Net cash position 2024 * | 304M | Net cash position 2025 * | 314M | EV / Sales 2025 * | 12.8 x |
P/E ratio 2024 * |
-4.03
x | P/E ratio 2025 * |
-3.92
x | Employees | 117 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.1% |
Latest transcript on AnaptysBio, Inc.
1 day | +2.48% | ||
1 week | -6.91% | ||
Current month | -1.44% | ||
1 month | +5.64% | ||
3 months | +9.00% | ||
6 months | +71.48% | ||
Current year | +12.00% |
Managers | Title | Age | Since |
---|---|---|---|
Daniel Faga
CEO | Chief Executive Officer | 44 | 21-11-25 |
Dennis Mulroy
DFI | Director of Finance/CFO | 69 | 20-07-14 |
Paul Lizzul
CTO | Chief Tech/Sci/R&D Officer | 49 | 20-07-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Hollings Renton
BRD | Director/Board Member | 77 | 15-06-29 |
Dennis Fenton
BRD | Director/Board Member | 72 | 18-03-04 |
Magda Marquet
BRD | Director/Board Member | 65 | 21-01-17 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.08% | 0 M€ | 0.00% | - | |
0.07% | 0 M€ | 0.00% | - | |
0.02% | 430 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-13 | 23.99 | +2.48% | 433,285 |
24-05-10 | 23.41 | -10.75% | 325,459 |
24-05-09 | 26.23 | +1.86% | 226,338 |
24-05-08 | 25.75 | +0.27% | 244,164 |
24-05-07 | 25.68 | -0.35% | 320,769 |
Delayed Quote Nasdaq, May 13, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.00% | 655M | |
+5.66% | 111B | |
+11.23% | 105B | |
-2.85% | 21.93B | |
-12.15% | 22.34B | |
-7.66% | 18.59B | |
-36.52% | 18.12B | |
-10.09% | 16.96B | |
+3.33% | 13.7B | |
+36.58% | 12.45B |
- Stock Market
- Equities
- ANAB Stock